Schizophrenia Bulletin Advance Access originally published online on April 2, 2009
Schizophrenia Bulletin 2009 35(3):491-492; doi:10.1093/schbul/sbp014
© The Author 2009. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.
Chlorpromazine Dose for People With Schizophrenia
Saskia de Haan1,2 and
Xiaomeng Liu2
2 University of Utrecht, UMC Utrecht, The Netherlands
Keywords: chlorpromazine / dose / meta-analysis
| The first 10% of the full text of this article appears below. |
 |
Background
|
|---|
Chlorpromazine is one of the 3 listed medicines for treating
psychotic disorders in the World Health Organization's Essential
Drug List. It is used across the globe for the 1% of people
who suffer from this illness. Chlorpromazine has many adverse
effects, including a range of movement disorders and anticholinergic
and antihistaminic effects. Higher doses
. . . [Full Text of this Article]
 |
Objectives
|
|---|
 |
Search Methods
|
|---|
 |
Selection Criteria
|
|---|
 |
Data Collection and Analysis
|
|---|
 |
Results
|
|---|
 |
Authors Conclusions
|
|---|
1 To whom correspondence should be addressed; tel: 00 31 64 28 10 903, e-mail: s.f.dehaan@students.uu.nl.

CiteULike
Connotea
Del.icio.us What's this?